Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Vijaypd Ceutical IPO
Price Band
₹
Issue Size
₹19.25 Cr
Lot Size
4,000 shares
Min Investment
₹280,000
2 LOTS MIN
GMP
—
Issue Price
₹35.0
Vijaypd Ceutical IPO AI Summary
- Vijaypd Ceutical IPO is listed on NSE SME in the Pharmacy Retail sector.
- Subscription window: 29 Sep–01 Oct 2025, listing on 07 Oct 2025.
Vijaypd Ceutical Limited is a well-established pharmaceutical distributor with a diverse product offering and a strong distribution network. The company has shown significant growth in both revenue and profit over recent periods. With a planned IPO to raise ₹19.25 Cr, the funds will be used for capital expenditure, debt repayment, and other corporate purposes. Investors should consider their risk profile and the potential for volatility when evaluating this IPO.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Vijaypd Ceutical IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 01 Oct 2025 — not a current signal.
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Vijaypd Ceutical IPO Grey Market Premium (GMP) Today
GMP not available yet
Grey Market Premium is updated daily. Check back closer to the listing date.
About the Company
Incorporated in October 1971, Vijaypd Ceutical Limited distributes pharmaceutical products and consumer goods, offering a comprehensive range of services. The company acts as representatives, dealers, agents, stockists, suppliers, traders, and packers. The company serves the pharmaceutical and wellness industries, as well as the FMCG market, offering products like medicines (injections, tablets, capsules, ointments, suppositories, ophthalmic preparations, liquid oral products), vitamins, hormones, enzymes, wellness tonics, serums, diagnostic test kits, personal care items (soaps, sanitizers, baby care), ayurvedic products, cosmetics, food products, dental products, and crude drugs. As of Marc 31, 2025, the company serves over r 2,109 pharmacies, clinics, and nursing homes across four districts, covering 20 locations. The company's distribution network connects with over 170 healthcare product manufacturers, providing access to more than 19,000 SKUs. This product portfolio allows the company to meet customer needs while ensuring quality and reliability in pharmaceutical supply. The company is a pharmaceutical distributor with FDA, FSSAI, and BMC certifications. Competitive Strength: Strengthen its market position by increasing its long-term relationships with its clients. Comprehensive product portfolio. Streamlined supply chain management. Experienced management team with proven execution capabilities.
Company Financials (₹ Cr)
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 57.15 | 33.27 | 32.87 |
| Total Income | 107.59 | 54.34 | 50.59 |
| Profit After Tax | 4.80 | 1.65 | 0.18 |
| EBITDA | 8.59 | 4.87 | 1.32 |
| NET Worth | 32.17 | 1.00 | 4.93 |
| Reserves and Surplus | 18.14 | ||
| Total Borrowing | 21.77 | 30.04 | 25.56 |
Key Ratios
NAV
₹25.78
ROE
28.91%
ROCE
17.30%
RoNW
14.91%
PAT Margin
4.49%
Debt/Equity
0.68
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Entero Healthcare Solutions Limited | 379.33 | 1.17% | 256.17 | 4.41 | 4.41 |
| MedPlus Health Services Limited | 103.63 | 3.32% | 249.42 | 3.37 | 3.37 |
| Vijaypd Ceutical Limited This IPO | 25.78 | 14.91% | 9.11 | 3.84 | 3.84 |
Promoters
Samit Madhukar Shah, Bhavin Dhirendra Shah, Rahul Dhirendra Shah, Narendra Nagindas Shah, Dina Madhukar Shah and Hemanti Jitendra Shah
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Funding of capital expenditure requirements of the company towards the construction of Pharmaceutical API/ Intermediates and Chemicals manufacturing plant and purchase of machineries in MIDC-Shrirampur, Ahmednagar, Maharashtra 10.83 2 Repayment/prepayment of all or certain of the borrowings availed of by the Company 5.10 3 General Corporate Purposes 0.74 4 Issue Expenses 2.58 Total 19.25
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total Income was ₹50.59 Cr in the period ending 31 Mar 2023, rising to ₹54.34 Cr by 31 Mar 2024, and further increasing to ₹107.59 Cr by 31 Mar 2025. This shows a significant growth trend over the three periods.
Profit Trend
Profit After Tax was ₹0.18 Cr for the period ending 31 Mar 2023, increasing to ₹1.65 Cr by 31 Mar 2024, and further rising to ₹4.80 Cr by 31 Mar 2025. This indicates a strong upward trend in profitability over the reported periods.
Valuation
Vijaypd Ceutical Limited has an implied P/E of 9.11 at the issue price, compared to peers trading at P/E ratios of approximately 249.42 to 256.17.
Grey Market Premium, Explained
The grey market refers to the unofficial trading of shares before they are listed on the stock exchange. The Grey Market Premium (GMP) indicates the expected listing gain or loss based on demand and supply dynamics in the grey market. A positive GMP suggests that investors expect the stock to list at a premium, while a negative GMP indicates the opposite.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their overall portfolio strategy and risk tolerance. It's important to consider the company's growth potential and market conditions.
Who May Want to Wait
Investors who are risk-averse or prefer stable investments may want to avoid IPOs like this, which can be subject to significant price fluctuations in the initial trading period.
IPO Timeline, Explained
The IPO process includes several key dates: the issue opens on 29 September 2025 and closes on 1 October 2025. Allotment of shares will be done by 3 October 2025, and the listing date is set for 7 October 2025.
Listing Gains — The Risk
Listing gains refer to the potential profit an investor can make when a stock lists at a price higher than the issue price. However, these gains are not guaranteed and can be influenced by market conditions, investor sentiment, and overall demand for the stock. Investors should be aware of the risks involved in trading on listing day.
This evaluation is generated from Vijaypd Ceutical's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
When does Vijaypd Ceutical IPO open and close?
Vijaypd Ceutical IPO opens on 29 September 2025 and closes on 01 October 2025.
When does Vijaypd Ceutical IPO list on the stock exchange?
Vijaypd Ceutical IPO listed on 07 October 2025 at ₹35.0.
What is the lot size for Vijaypd Ceutical IPO?
The lot size for Vijaypd Ceutical IPO is 4000 shares, requiring a minimum investment of ₹280,000 (2 lots).
What is the issue price of Vijaypd Ceutical Limited?
The issue price is ₹35.0.
What is the lot size for the IPO?
The lot size is 4000 shares.
When does the IPO open and close?
The IPO opens on 29 September 2025 and closes on 1 October 2025.
What is the minimum investment required?
The minimum investment required is ₹280,000.
When is the listing date for the shares?
The listing date is 7 October 2025.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
29 Sep 2025
Close
01 Oct 2025
Allotment
03 Oct 2025
Listing
07 Oct 2025
Similar IPOs in Pharmacy Retail
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Vijaypd Ceutical?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.